

=> b reg  
FILE 'REGISTRY' ENTERED AT 14:16:34 ON 06 JUN 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 5 JUN 2007 HIGHEST RN 936615-27-9  
DICTIONARY FILE UPDATES: 5 JUN 2007 HIGHEST RN 936615-27-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d que sta 117  
L15 STR



REP G1=(1-20) C  
VAR G2=O/S  
NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE  
L17 35 SEA FILE=REGISTRY SSS FUL L15

100.0% PROCESSED 25388 ITERATIONS  
SEARCH TIME: 00.00.01

35 ANSWERS

=> b hcap

FILE 'HCAPLUS' ENTERED AT 14:16:47 ON 06 JUN 2007  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.


FILE COVERS 1907 - 6 Jun 2007 VOL 146 ISS 24  
 FILE LAST UPDATED: 5 Jun 2007 (20070605/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitstr retable 113

L13	ANSWER 1 OF 1	HCAPLUS	COPYRIGHT 2007 ACS on STN		
AN	2004:610069	HCAPLUS			
DN	141:140475				
TI	Preparation of macrocyclic $\beta$ -secretase inhibitors for treatment of Alzheimer's disease				
IN	Coburn, Craig A.; Stachel, Shawn J.; Vacca, Joseph P.				
PA	Merck & Co., Inc., USA				
SO	PCT Int. Appl., 44 pp.				
	CODEN: PIXXD2				
DT	Patent				
LA	English				
FAN.CNT	1				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2004062625	A2	20040729	2004WO-US00085	20040102
	WO2004062625	A3	20050331		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
	AU2004204692	A1	20040729	2004AU-0204692	20040102
	CA---2512111	A1	20040729	2004CA-2512111	20040102
	EP---1583750	A2	20051012	2004EP-0700071	20040102
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP2006515881	T	20060608	2006JP-0500780	20040102
	US2006058278	A1	20060316	2005US-0541476	20050706
PRAI	2003US-438630P	P	20030107		
	2004WO-US00085	W	20040102		
OS	MARPAT 141:140475				
GI					



AB    Macrocycles of formula I [R1 = H, alkyl, cycloalkyl, (substituted) Ph, etc.; R2 = H, alkyl-SO2N(alkyl), CN, halo, etc.; R3 = CH2OH, CHO, acyl, CH2NH2, CONH2, etc.; X = (CH2)<sub>m</sub>; m = 1-4] are prepared which are inhibitors of the  $\beta$ -secretase enzyme and are useful in the treatment or prevention of diseases in which  $\beta$ -secretase is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compns. comprising these compds. and the use of these compds. and compns. in the prevention or treatment of such diseases in which  $\beta$ -secretase is involved. Thus, II was prepared in several steps from dibenzyl 5-aminoisophthalate, dl-meta-tyrosine and Boc-L-phenylglycinol. The compds. had IC50 values from about 1 nM to 1  $\mu$ M against  $\beta$ -secretase.

IT 725725-36-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of macrocyclic  $\beta$ -secretase inhibitors for treatment of Alzheimer's disease)

RN 725725-36-0 HCAPLUS

CN Butanamide, 2-[[[[(4S,13S)-13-methyl-18-[methyl(methylsulfonyl)amino]-2,15-dioxa-11-oxa-3,14-diazatricyclo[14.3.1.16,10]heneicosa-1(20),6,8,10(21),16,18-hexaen-4-yl]methyl]amino]-N-(2-methylpropyl)-, (2S)- (9CI) (CA INDEX NAME)

### Absolute stereochemistry.




```
=> d bib abs hitind fhitstr retable 127 tot
```

L27 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN  
AN 2006:1149497 HCAPLUS

DN 146:19371  
 TI Macroyclic Inhibitors of  $\beta$ -Secretase: Functional Activity in an Animal Model. [Erratum to document cited in CA145:465146]  
 AU Stachel, Shawn J.; Coburn, Craig A.; Sankaranarayanan, Sethu; Price, Eric A.; Wu, Guoxin; Crouthamel, Michelle; Pietrak, Beth L.; Huang, Qian; Lineberger, Janet; Espeseth, Amy S.; Jin, Lixia; Ellis, Joan; Holloway, M. Katharine; Munshi, Sanjeev; Allison, Timothy; Hazuda, Daria; Simon, Adam J.; Graham, Samuel L.; Vacca, Joseph P.  
 CS Department of Medicinal Chemistry, Biological Chemistry, Molecular Systems and Structural Biology, Merck Research Laboratories, West Point, PA, 19486, USA  
 SO Journal of Medicinal Chemistry (2006), 49(24), 7252  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PB American Chemical Society  
 DT Journal  
 LA English  
 AB Guoxin Wu and Michelle Crouthamel were inadvertently omitted from the author list. Their affiliation is the Department of Biol. Chemical, represented by the double dagger symbol in the paper. The correct author list is given.  
 CC 1-3 (Pharmacology)  
 Section cross-reference(s): 34  
 IT 725725-37-1P 725725-38-2P 847157-19-1P 847157-32-8P  
 913625-93-1P 913626-00-3P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
     (macrocyclic inhibitors of  $\beta$ -secretase and functional activity in an animal model (Erratum))  
 IT 12135-22-7P, Pearlman's catalyst 50765-19-0P, Methyl-3-Iodo-5-nitrobenzoate 184176-05-4P 217314-45-9P, Methyl 3-amino-5-iodobenzoate 725725-42-8P 725725-51-9P 725725-52-0P 725725-55-3P  
 760894-94-8P 847157-47-5P 847157-48-6P 847157-49-7P 847157-50-0P  
 847157-51-1P 847157-52-2P 847157-53-3P 847157-54-4P 913625-97-5P  
 913626-02-5P 913626-03-6P 913626-04-7P 913626-05-8P 913626-06-9P  
 913626-07-0P 913626-08-1P 913626-09-2P 913626-11-6P 913626-12-7P  
 913626-13-8P 913626-15-0P 913626-16-1P 913626-17-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
     (macrocyclic inhibitors of  $\beta$ -secretase and functional activity in an animal model (Erratum))  
 IT 725725-37-1P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
     (macrocyclic inhibitors of  $\beta$ -secretase and functional activity in an animal model (Erratum))  
 RN 725725-37-1 HCPLUS  
 CN Methanesulfonamide, N-[(4S)-4-(hydroxymethyl)-2,15-dioxo-11-oxa-3,14-diazatricyclo[14.3.1.16,10]heneicosa-1(20),6,8,10(21),16,18-hexaen-18-yl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



L27 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2006:908572 HCAPLUS  
 DN 145:465146

TI Macrocyclic Inhibitors of  $\beta$ -Secretase: Functional Activity in an Animal Model

AU Stachel, Shawn J.; Coburn, Craig A.; Sankaranarayanan, Sethu; Price, Eric A.; Pietrak, Beth L.; Huang, Qian; Lineberger, Janet; Espeseth, Amy S.; Jin, Lixia; Ellis, Joan; Holloway, M. Katharine; Munshi, Sanjeev; Allison, Timothy; Hazuda, Daria; Simon, Adam J.; Graham, Samuel L.; Vacca, Joseph P.

CS Department of Medicinal Chemistry, Biological Chemistry, Molecular Systems and Structural Biology, Merck Research Laboratories, West Point, PA, 19486, USA

SO Journal of Medicinal Chemistry (2006), 49(21), 6147-6150  
 CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

AB A macrocyclic inhibitor of  $\beta$ -secretase was designed by covalently crosslinking the P1 and P3 side chains of an isophthalamide-based inhibitor. Macrocyclization resulted in significantly improved potency and phys. properties when compared to the initial lead structures. More importantly, these macrocyclic inhibitors also displayed in vivo amyloid lowering when dosed in a murine model.

CC 1-3 (Pharmacology)

Section cross-reference(s): 34

IT 725725-37-1P 725725-38-2P 847157-19-1P 847157-32-8P

913625-93-1P 913626-00-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(macrocyclic inhibitors of  $\beta$ -secretase and functional activity in an animal model)

IT 12135-22-7P, Pearlman's catalyst 50765-19-0P, Methyl-3-Iodo-5-nitrobenzoate 184176-05-4P 217314-45-9P, Methyl 3-amino-5-iodobenzoate 725725-42-8P 725725-51-9P 725725-52-0P 725725-53-1P  
 725725-55-3P 760894-94-8P 847157-47-5P 847157-48-6P  
 847157-49-7P 847157-50-0P 847157-51-1P 847157-52-2P 847157-53-3P  
 847157-54-4P 913625-97-5P 913626-02-5P 913626-03-6P 913626-04-7P  
 913626-05-8P 913626-06-9P 913626-07-0P 913626-08-1P 913626-09-2P  
 913626-11-6P 913626-12-7P 913626-13-8P 913626-15-0P 913626-16-1P  
 913626-17-2P 928823-83-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(macrocyclic inhibitors of  $\beta$ -secretase and functional activity in an animal model)

IT 725725-37-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(macrocyclic inhibitors of  $\beta$ -secretase and functional activity in an animal model)

RN 725725-37-1 HCAPLUS

CN Methanesulfonamide, N-[(4S)-4-(hydroxymethyl)-2,15-dioxo-11-oxa-3,14-diazatricyclo[14.3.1.16,10]heneicosa-1(20),6,8,10(21),16,18-hexaen-18-yl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Beher, D	2005	14	1385	Expert Opin Invest D	HCAPLUS
Best, B	2005	313	902	Pharmacol Exp Ther	
Brady, S	2004	14	601	Bioorg Med Chem Lett	HCAPLUS
Cai, H	2001	4	233	Nat Neurosci	HCAPLUS
Coburn, C	2006	16	3635	Bioorg Med Chem Lett	HCAPLUS
Goate, A	1991	349	523	Nature	
Hannessian, S	2006	49	4544	J Med Chem	
Hardy, J	1997	349	704	Proc Natl Acad Sci U	
Hu, X	2004	47	4941	J Med Chem	HCAPLUS
Lamb, B	1993	5	22	Nat Genet	HCAPLUS
Lamb, B	1993	5	22	Nature Genetics	HCAPLUS
Milano, J	2004	82	341	Toxicol Sci	HCAPLUS
Roberds, S	2001	10	1317	Hum Mol Genet	HCAPLUS
Rojo, I	2006	16	191	Bioorg Med Chem Lett	HCAPLUS
Sankaranarayanan, S	2006			10th International c	
Savage, M	1998	18	1743	J Neurosci	HCAPLUS
Scholl, M	1999	1	953	Org Lett	HCAPLUS
Searfoss, G	2003	278	46107	J Biol Chem	HCAPLUS
Selkoe, D	1996	271	18295	J Biol Chem	HCAPLUS
Selkoe, D	1999	399A	23	Nature	
Simon, A	2005			2005 AD/PD meeting	
Sinha, S	1999	96	11049	Proc Natl Acad Sci U	HCAPLUS
Stachel, S	2006	16	641	Bioorg Med Chem Lett	HCAPLUS
Stachel, S	2004	47	6117	J Med Chem	
Stachel, S	2004	47	6447	J Med Chem	HCAPLUS
Thompson, L	2005	11	3383	Curr Pharm Des	HCAPLUS
Tilley, J	1991	34	1125	J Med Chem	HCAPLUS
Tsantrizos, Y	2003	42	1356	Angew Chem, Int Ed	HCAPLUS

L27 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:610069 HCAPLUS

DN 141:140475

TI Preparation of macrocyclic  $\beta$ -secretase inhibitors for treatment of Alzheimer's disease

IN Coburn, Craig A.; Stachel, Shawn J.; Vacca, Joseph P.


PA Merck & Co., Inc., USA

SO PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DT Patent  
LA English  
FAN.CNT 1

PATENT NO.		KIND	DATE	APPLICATION NO.	DATE
PI	WO2004062625	A2	20040729	2004WO-US00085	20040102 <--
	WO2004062625	A3	20050331		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
	AU2004204692	A1	20040729	2004AU-0204692	20040102 <--
	CA---2512111	A1	20040729	2004CA-2512111	20040102 <--
	EP---1583750	A2	20051012	2004EP-0700071	20040102 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP2006515881	T	20060608	2006JP-0500780	20040102 <--
	US2006058278	A1	20060316	2005US-0541476	20050706 <--
PRAI	2003US-438630P	P	20030107	<--	
	2004WO-US00085	W	20040102	<--	
OS	MARPAT 141:140475				
GI					



AB Macrocycles of formula I [R1 = H, alkyl, cycloalkyl, (substituted) Ph, etc.; R2 = H, alkyl-SO2N(alkyl), CN, halo, etc.; R3 = CH2OH, CHO, acyl, CH2NH2, CONH2, etc.; X = (CH2)<sub>m</sub>; m = 1-4] are prepared which are inhibitors of the  $\beta$ -secretase enzyme and are useful in the treatment or prevention of diseases in which  $\beta$ -secretase is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compns. comprising these compds. and the use of these compds. and compns. in the prevention or treatment of such diseases in which  $\beta$ -secretase is involved. Thus, II was prepared in several steps from dibenzyl 5-aminoisophthalate, dl-meta-tyrosine and Boc-L-phenylglycinol. The compds. had IC50 values from about 1 nM to 1  $\mu$ M against  $\beta$ -secretase.

IC ICM A61K

CC 28-23 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross-reference(s): 1, 63

IT 725725-35-9P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of macrocyclic  $\beta$ -secretase inhibitors for treatment of Alzheimer's disease)

IT 725725-31-5P 725725-32-6P 725725-33-7P  
725725-34-8P 725725-36-0P 725725-37-1P  
725725-38-2P 725725-39-3P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

L9 12 L8 AND NRRS>=3  
L10 37 C30H43N5O6S  
L11 2 L10 AND NRRS>=3  
SEL RN 1  
L12 1 E1 AND L11

FILE 'HCAPLUS' ENTERED AT 13:47:07 ON 06 JUN 2007  
L13 1 L12

FILE 'REGISTRY' ENTERED AT 13:47:26 ON 06 JUN 2007  
L14 STR  
L15 STR L14  
L16 1 L15  
L17 35 L16 FULL  
SAV TEM J476C1/A L17  
SEL RN 4-15  
L18 12 E2-13 AND L17  
L19 12 L18 AND L8

FILE 'HCAPLUS' ENTERED AT 14:12:55 ON 06 JUN 2007  
L20 3 L18

FILE 'HCAOLD' ENTERED AT 14:13:29 ON 06 JUN 2007  
L21 0 L18

FILE 'BIOSIS' ENTERED AT 14:13:40 ON 06 JUN 2007  
L22 0 L18

FILE 'USPATFULL, USPAT2' ENTERED AT 14:13:46 ON 06 JUN 2007  
L23 1 L18

FILE 'MEDLINE' ENTERED AT 14:14:08 ON 06 JUN 2007  
L24 0 L18

FILE 'EMBASE' ENTERED AT 14:14:12 ON 06 JUN 2007  
L25 0 L18

FILE 'HCAPLUS' ENTERED AT 14:14:52 ON 06 JUN 2007  
L26 3 L13,L20  
L27 3 L26 AND L1-6

=>

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of macrocyclic  $\beta$ -secretase inhibitors for treatment of Alzheimer's disease)

IT 34260-70-3P 725725-40-6P 725725-41-7P 725725-42-8P 725725-43-9P  
 725725-44-0P 725725-46-2P 725725-47-3P 725725-48-4P  
 725725-49-5P 725725-50-8P 725725-51-9P 725725-52-0P  
 725725-53-1P 725725-54-2P 725725-55-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of macrocyclic  $\beta$ -secretase inhibitors for treatment of Alzheimer's disease)

IT 725725-35-9P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of macrocyclic  $\beta$ -secretase inhibitors for treatment of Alzheimer's disease)

RN 725725-35-9 HCAPLUS

CN Methanesulfonamide, N-[(4S,13S)-4-(hydroxymethyl)-13-methyl-2,15-dioxo-11-oxa-3,14-diazatricyclo[14.3.1.16,10]heneicosa-1(20),6,8,10(21),16,18-hexaen-18-yl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 13:36:36 ON 06 JUN 2007)

FILE 'HCAPLUS' ENTERED AT 13:36:44 ON 06 JUN 2007

L1 1 US20060058278/PN OR (US2005-541476 OR WO2004-US00085 OR US2003-E COBURN C/AU

L2 2 E3

E COBURN CRAIG/AU

L3 71 E3-5

E STACHEL S/AU

L4 57 E3-4,E8-10

E VACCA J/AU

L5 193 E3,E6,E9-14

L6 34202 MERCK/CS, PA

FILE 'REGISTRY' ENTERED AT 13:39:40 ON 06 JUN 2007

FILE 'HCAPLUS' ENTERED AT 13:39:45 ON 06 JUN 2007

L7 TRA L1 1- RN : 36 TERMS

FILE 'REGISTRY' ENTERED AT 13:39:45 ON 06 JUN 2007

L8 36 SEA L7

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	13	(coburn stachel vacca).in. and macrocyclic.ti.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/06 15:14